該当箇所へ

MorphoSys社、Genedata Biologicsを導入:
研究開発データ管理を支援

Leader in therapeutic antibodies adopts Genedata Biologics for its central research and development IT infrastructure

September 27, 2011
Basel, Switzerland

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that MorphoSys AG will license Genedata Biologics™ as its R&D data management platform. MorphoSys, a pioneer in the field of therapeutic antibodies, will use Genedata Biologics to support internal and partner-based biologics discovery programs for lead finding and optimization. Genedata Biologics integrates with the MorphoSys laboratory infrastructure and interacts with proprietary discovery technologies, including the MorphoSys HUCAL® antibody library, screening, and expression platforms.

“Therapeutic antibodies are one of the fastest-growing drug classes in human healthcare,” said Dr. Markus Enzelberger, vice president and head of Discovery Alliances and Technologies at MorphoSys.  “To advance our leadership in this field, our biopharma R&D operations require an integrated and scalable informatics infrastructure that can be tailored to support our biologics discovery processes. Genedata Biologics provides comprehensive biologics data management functionality and the flexibility needed to support our proprietary antibody discovery processes and technology portfolio. And, it provides this functionality out-of-the-box, which saves valuable research time and money.”

First-in-Class Biologics Data Management
Genedata Biologics is the industry’s first-in-class biologics data management system. Out-of-the-box, it processes and manages data from diverse library, selection, screening, and expression technologies and strategies. It provides end-to-end laboratory workflow support, spanning:  library registration; selection and planning; screening; hit selection; expression; purification; and analytics.

The system’s integrated decision support tools enable the identification of the most promising molecules for development. These tools also provide transparent guidance for downstream expression, purification, characterization, and assessment of candidate molecules.

Inherently flexible, Genedata Biologics is easily configured to address corporate-specific and proprietary workflows and technology requirements. This is accomplished by an integrated yet open molecule and sample management platform, and interfaces for assay and analytics instrument integration. A comprehensive set of APIs enables integration with existing corporate IT infrastructures.

“MorphoSys is pioneering antibody discovery and we are delighted they have selected Genedata Biologics as their central discovery IT infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “MorphoSys’ adoption of Genedata Biologics is another major milestone for our growing biopharma business. We will continue to invest in the advancement of protein therapeutics, and support those engaged in the field including pharmaceutical and biotechnology companies, technology providers, CROs, CMOs, and emerging biosimilar companies.”


Genedata Biologics provides the flexibility needed to support our proprietary antibody discovery processes and technology portfolio out-of-the-box, which saves valuable research time and money

Dr. Markus Enzelberger
Vice President and Head of Discovery Alliances and Technologies